GRI Bio Q3 Loss Narrows to $1.5M; Going Concern and Nasdaq MVLS Risk Persist
GRI sits 25% above its 52-week low of $1.36 on light trading volume (0.1× avg).
Summary
GRI Bio's Q3 2026 net loss narrowed to $1.5 million with $9.5 million of cash, but the company still flags substantial doubt about going concern and sits below the $5 million Nasdaq MVLS threshold that a stayed listing rule would enforce.
Key Events · Earnings and Guidance · GRI
-
Q3 Loss Narrows on Trial Wind-Down
Net loss was $1.5 million for Q3 2026 versus $3.4 million in Q3 2025, as R&D spending fell to $0.2 million from $1.8 million after the Phase 2a trial completed.
-
Cash Rises to $9.5 Million
Cash and equivalents were $9.5 million at September 30, 2026, up from $8.2 million at December 31, 2025, after $8.2 million of gross ATM proceeds in the first nine months; no ATM shares were sold in Q3.
-
Runway Only Covers Preliminary Work
Management expects cash to fund operations into Q2 2027, but only assuming it continues preliminary work toward additional GRI-0621 studies; completing those studies requires substantial additional capital.
-
Going Concern Doubt Reiterated
The filing states substantial doubt about the company's ability to continue as a going concern for one year from issuance, citing an accumulated deficit of $56.8 million.
Analysis · GRI · Life Sciences
Cash burn eased this quarter as the Phase 2a trial wound down, with the net loss falling to $1.5 million from $3.4 million a year ago, while cash rose to $9.5 million after $8.2 million of ATM sales in the first nine months. That runway statement, however, is narrower than it looks: management says the cash lasts into Q2 2027 only if it sticks to preliminary work on GRI-0621, and it cannot complete the additional dose-ranging and other studies without substantial new capital. Substantial doubt about the company's ability to continue as a going concern is reiterated in the filing, which also adds a listing overhang. The company's market value of listed securities is below $5 million, and a new Nasdaq MVLS requirement approved July 22, 2026 — currently stayed pending SEC review — would trigger immediate suspension and delisting proceedings after 30 business days below the threshold, with no cure period. A material weakness in internal controls also remains unremediated, though management implemented compensating controls in Q2 2026. With a market cap of roughly $3.7 million, any further equity raise would be heavily dilutive.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRI was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $1.36 to $64.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.